Is the increase in orchiectomy for prostate cancer patients appropriate?

Cancer

Volumn 112, Issue 10, 2008, Pages 2106-2107

  Chodak, Gerald W ^a  

^a Midwest Prostate and Urology Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST;

CANCER PATIENT; CASTRATION; ECONOMIC ASPECT; EDITORIAL; HUMAN; MEDICARE; ORCHIECTOMY; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; UROLOGY;

DRUG UTILIZATION; GONADOTROPIN-RELEASING HORMONE; HEALTH CARE COSTS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 43049116131     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23417     Document Type: Editorial

References (2)

1. Huggins C, Hodges CV. Studies on prostatic cancer: effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
2. Weight CJ, Klein EA. Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008;112:2195-2201.